Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to get Screeners that run automatically with the results emailed to you! FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Xenon Pharmaceuticals Inc (XENE)

Xenon Pharmaceuticals Inc (XENE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Xenon Pharmaceuticals Inc 200 - 3650 GILMORE WAY BURNABY A1 V5G 4W8 CAN

www.xenon-pharma.com P: 604-484-3300 F: 604-484-3450

Description:

Xenon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It is focused on the development of medicines through the application of its proprietary discovery platform, which it refer to as Extreme Genetics. Xenon is developing proprietary product candidates for the treatment of both orphan as well as more prevalent diseases. The company offers Glybera (R), a gene therapy for the treatment of lipoprotein lipase deficiency, an orphan disorder. Xenon Pharmaceuticals Inc. is headquartered in Burnaby, Canada.

Key Statistics

Overview:

Market Capitalization, $K 2,979,564
Enterprise Value, $K 2,830,924
Shares Outstanding, K 75,432
Annual Sales, $ 0 K
Annual Net Income, $ -182,390 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -44,740 K
EBIT, $ -214,040 K
EBITDA, $ -210,500 K
60-Month Beta 1.15
% of Insider Shareholders 5.43%
% of Institutional Shareholders 95.45%
Float, K 71,336
% Float 94.57%
Short Volume Ratio 0.56

Growth:

1-Year Return 1.66%
3-Year Return 115.61%
5-Year Return 322.01%
5-Year Revenue Growth 0.00%
5-Year Earnings Growth -105.26%
5-Year Dividend Growth 0.00%

Per-Share Information:

Most Recent Earnings -0.64 on 02/29/24
Latest Earnings Date 05/14/24
Earnings Per Share ttm -2.72
EPS Growth vs. Prev Qtr 12.33%
EPS Growth vs. Prev Year -12.28%
Annual Dividend Yield 0.00%
Dividend Payout Ratio 0.00%

XENE Ratios

Ratio
Price/Earnings ttm 0.00
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -25.18%
Return-on-Assets % -23.99%
Profit Margin % 0.00%
Debt/Equity 0.00
Price/Sales N/A
Price/Cash Flow N/A
Price/Book 2.82
Book Value/Share 14.18
Interest Coverage -2.93
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar